Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Accured Expenses (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Change in Accured Expenses for 3 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 122.39% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 45.2% year-over-year, with the annual reading at $2.4 million for FY2025, 45.2% up from the prior year.
  • Change in Accured Expenses hit $5.3 million in Q4 2025 for NewAmsterdam Pharma, up from $638000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.3 million in Q3 2023 to a low of -$5.8 million in Q4 2023.
  • Historically, Change in Accured Expenses has averaged $800333.3 across 3 years, with a median of $520000.0 in 2024.
  • Biggest YoY gain for Change in Accured Expenses was 431.0% in 2025; the steepest drop was 258.65% in 2025.
  • Year by year, Change in Accured Expenses stood at -$5.8 million in 2023, then skyrocketed by 141.3% to $2.4 million in 2024, then skyrocketed by 122.39% to $5.3 million in 2025.
  • Business Quant data shows Change in Accured Expenses for NAMS at $5.3 million in Q4 2025, $638000.0 in Q3 2025, and $1.4 million in Q2 2025.